These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3437901)

  • 1. Structural considerations in idiotype vaccine design.
    Kieber-Emmons T; Ward MM; Ward RE; Kohler H
    Monogr Allergy; 1987; 22():126-33. PubMed ID: 3437901
    [No Abstract]   [Full Text] [Related]  

  • 2. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lectin-based idiotype vaccines for polysaccharide antigens.
    Ravindran B
    Immunol Today; 1991 Jun; 12(6):207. PubMed ID: 1878136
    [No Abstract]   [Full Text] [Related]  

  • 4. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network.
    Weathington NM; Blalock JE
    Expert Rev Vaccines; 2003 Feb; 2(1):61-73. PubMed ID: 12901598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants of the human idiotype HibId-1.
    Reason DC; O'Connor AP; Lucas AH
    J Mol Recognit; 2001; 14(6):393-400. PubMed ID: 11757072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can anti-idiotype vaccine help to circumvent parasite escape mechanisms?
    Grzych JM; Del Guidice G; Capron M; Capron A; Lambert PH
    Monogr Allergy; 1987; 22():172-9. PubMed ID: 3437902
    [No Abstract]   [Full Text] [Related]  

  • 8. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.
    Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Zabalegui N; Villanueva H; Bendandi M
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):1-7. PubMed ID: 15363462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to immunization against infectious agents. Use of anti-idiotypes.
    Finberg RW
    Year Immunol; 1985; ():175-81. PubMed ID: 3879907
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new approach to vaccine development: anti-idiotypic vaccines].
    Lambert PH; Spertini F; Del Giudice G
    Ther Umsch; 1986 Feb; 43(2):155-9. PubMed ID: 3515611
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
    Tao MH; Levy R
    Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-idiotype antibody as a prospective vaccine against hepatitis B.
    Korec E; Hlozánek I; Stará J; Nĕmecek V
    Folia Biol (Praha); 1987; 33(2):98-103. PubMed ID: 3595919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Past, present and future of anti-idiotype vaccination].
    Rodríguez Calvillo M; Inogés S; López Díaz de Cerio A; Zabalegui N; Panizo C; Hernández M; Pérez Calvo J; Prósper F; Melero I; Sánchez-Ibarrola A; Rocha E; Bendandi M
    Rev Med Univ Navarra; 2004; 48(3):14-23. PubMed ID: 15622921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
    Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
    Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiotypes as internal antigens.
    Kohler H; McNamara M; Ward RE
    Prog Clin Biol Res; 1985; 172B():343-53. PubMed ID: 3991719
    [No Abstract]   [Full Text] [Related]  

  • 19. Structural characterization of syngeneic and allogeneic anti-idiotypic antibodies in the anti-arsonate system.
    Meek K; Jeske D; Alkan S; Urbain J; Capra JD
    Monogr Allergy; 1987; 22():109-19. PubMed ID: 3501827
    [No Abstract]   [Full Text] [Related]  

  • 20. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer.
    Fernández LE; Alonso DF; Gomez DE; Vázquez AM
    Expert Rev Vaccines; 2003 Dec; 2(6):817-23. PubMed ID: 14711364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.